Processing Your Payment

Please do not leave this page until complete. This can take a few moments.

March 30, 2015

RXi grows 4Q revenue, cuts losses

RXi Pharmaceuticals of Marlborough, which is pushing toward federal approval of its initial products, saw 8.3-percent revenue growth in the final quarter of 2014 while paring its quarterly loss over the fourth quarter of 2013.

RXi, which is seeking approval of a drug that would reduce the formation of post-surgical scars, lost $2.76 million during the quarter on revenue of $1.56 million. In the fourth quarter of 2013, the company brought in $1.44 million in revenue and lost $3.72 million.

For the full year, RXi brought in $5.68 million in revenue, down nearly 68 percent over 2013. Net losses decreased substantially, from $29.5 million in 2013 to $12.93 million last year.

During the fourth quarter, RXi completed enrollment of subjects for the Phase 2a clinical study of RXi-109, the anti-scarring drug while also getting the first results from that study. In a statement, President and CEO Geert Cauwenbergh said the company is “well positioned” to keep growing in 2015, while focusing on keeping as much of its $8.5 million in cash as possible. That amount is down nearly 25 percent from the $11.39 million the company held at the end of 2013. Cauwenbergh said the cash “burn” for RXi is in line with expectations for a biotechnology firm “that is in mid-stage development with its first two products.”

The other product, Samcyprone, is also in Phase 2 trials. It is being evaluated as a potential treatment for warts and to prevent the spread of malignant melanomas. In December, RXi acquired the licensing rights to the drug.

Sign up for Enews

WBJ Web Partners

Related Content

0 Comments

Order a PDF